Amylyx Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Amylyx Pharmaceuticals, Inc. (AMLX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $6.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $2.85M.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $3.16M, a 3061.00% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $931.00K, a 365.50% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $769.00K, a 669.00% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $1.80M, a 80.00% increase from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $1.00M, a 95.15% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $20.60M, a 45.07% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $14.20M, a 129.03% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $6.01M 10-Q · filed 2026-08-06 | $6.94M derived: sum of 3 quarters · filed 2026-08-06 | $7.71M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $3.16M 10-Q · filed 2026-05-07 | $4.09M derived: sum of 2 quarters · filed 2026-05-07 | $4.86M derived: sum of 3 quarters · filed 2026-05-07 | $4.86M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $931.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.70M derived: sum of 2 quarters · filed 2026-03-03 | $1.70M derived: sum of 3 quarters · filed 2026-08-06 | $1.80M 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $769.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $769.00K derived: sum of 2 quarters · filed 2026-08-06 | $869.00K 10-Q · filed 2025-11-06 | $1.07M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $100.00K 10-Q · filed 2026-08-06 | $80.00K 10-Q · filed 2025-08-07 | $300.00K derived: sum of 3 quarters · filed 2026-08-06 | $400.00K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-07 | $77.00K 10-Q · filed 2025-05-08 | $300.00K derived: sum of 2 quarters · filed 2026-05-07 | $400.00K derived: sum of 3 quarters · filed 2026-05-07 | $400.00K derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $300.00K derived: sum of 2 quarters · filed 2026-03-03 | $300.00K derived: sum of 3 quarters · filed 2026-03-03 | $1.00M 10-K · filed 2026-03-03 | |||
| 2024-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $100.00K derived: sum of 2 quarters · filed 2025-11-06 | $800.00K 10-Q · filed 2025-11-06 | $780.00K 10-Q · filed 2024-11-07 | $3.00M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $700.00K 10-Q · filed 2025-08-07 | $745.00K 10-Q · filed 2024-08-08 | $2.90M derived: sum of 3 quarters · filed 2025-08-07 | $5.10M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $700.00K 10-Q · filed 2025-05-08 | $653.00K 10-Q · filed 2024-05-09 | $2.90M derived: sum of 2 quarters · filed 2025-05-08 | $5.10M derived: sum of 3 quarters · filed 2025-05-08 | $9.60M derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $4.40M derived: sum of 2 quarters · filed 2025-03-04 | $8.90M derived: sum of 3 quarters · filed 2025-03-04 | $20.60M 10-K · filed 2025-03-04 | |||
| 2023-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $6.70M derived: sum of 2 quarters · filed 2024-11-07 | $18.40M 10-Q · filed 2024-11-07 | $18.36M 10-Q · filed 2023-11-09 | $26.60M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $4.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $16.20M 10-Q · filed 2024-08-08 | $16.20M 10-Q · filed 2023-08-10 | $24.40M derived: sum of 3 quarters · filed 2024-08-08 | $24.40M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $11.70M 10-Q · filed 2024-05-09 | $11.68M 10-Q · filed 2023-05-11 | $19.90M derived: sum of 2 quarters · filed 2024-05-09 | $19.90M derived: sum of 3 quarters · filed 2024-05-09 | $25.90M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $8.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $8.20M derived: sum of 2 quarters · filed 2024-02-22 | $14.20M derived: sum of 3 quarters · filed 2024-02-22 | $14.20M 10-K · filed 2024-02-22 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $6.00M derived: sum of 2 quarters · filed 2023-11-09 | $6.00M 10-Q · filed 2023-11-09 | $5.96M 10-Q · filed 2022-11-10 | $7.70M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $6.00M 10-Q · filed 2023-08-10 | $5.96M 10-Q · filed 2022-08-11 | $7.70M derived: sum of 3 quarters · filed 2024-02-22 | $12.10M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $1.70M derived: sum of 2 quarters · filed 2024-02-22 | $6.10M derived: sum of 3 quarters · filed 2024-02-22 | $4.20M derived: sum of 4 quarters · filed 2024-02-22 | |||
| 2021-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $6.10M derived: sum of 2 quarters · filed 2024-02-22 | $4.20M derived: sum of 3 quarters · filed 2024-02-22 | $6.20M 10-K · filed 2024-02-22 | |||
| 2021-09-30 | $4.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.50M derived: sum of 2 quarters · filed 2022-11-10 | $4.50M 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | -$1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $100.00K 10-Q · filed 2022-08-11 | |||||
| 2021-03-31 | $2.00M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |